1291099-87-0

Basic information

• Product Name: 1-methyl-4-nitroso-5-phenyl-3-(trifluoromethyl)-1H-pyrazole
• Synonyms: 1-methyl-4-nitroso-5-phenyl-3-(trifluoromethyl)-1H-pyrazole
• CAS NO: 1291099-87-0
• Molecular Weight: 255.199
• Mol File: 1291099-87-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1-methyl-4-nitroso-5-phenyl-3-(trifluoromethyl)-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-methyl-4-nitroso-5-phenyl-3-(trifluoromethyl)-1H-pyrazole(1291099-87-0)
• EPA Substance Registry System: 1-methyl-4-nitroso-5-phenyl-3-(trifluoromethyl)-1H-pyrazole(1291099-87-0)

Safety Data

• Hazardous Substances Data: 1291099-87-0(Hazardous Substances Data)

Upstream product

• 60-34-4 methylhydrazine 
• 41463-86-9 4,4,4-trifluoro-3-hydroxy-1-phenylbut-2-en-1-one 
• 326-06-7 1-Phenyl-4,4,4-trifluorobutane-1,3-dione 
• 74-88-4 methyl iodide 

Downstream Products

• 1414573-15-1 1-methyl-5-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-amine 

Relevant articles and documents

Alternative approaches to the synthesis of polyfluoroalkyl-containing 1-methyl-4-nitrosopyrazoles

We studied different approaches to the synthesis of polyfluoroalkyl-containing 1-methyl-4-nitrosopyrazoles, which are based on the cyclization of 4,4,4-trifluoro-3,3-dihydroxy-2-hydroxyimino-1-R-butan-1-ones or 2-hydroxyimino-1,3-diketones with methylhydrazine and on a one-pot sequential treatment of 1,3-diketones with sodium nitrite and methylhydrazine. It was found that the regioselectivity of the formation of 1-methyl-4-nitrosopyrazoles is affected by the steric factors of 1,3-dicarbonyl reagents. The study of the mycostatic effect of 4-nitrosopyrazoles showed that the introduction of a bulky polyfluoroalkyl or tert-butyl substituent leads to a decrease in their activity.

THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN

Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.